Multicenter Comparison of Roche COBAS AMPLICOR MONITOR Version 1.5, Organon Teknika NucliSens QT with Extractor, and Bayer Quantiplex Version 3.0 for Quantification of Human Immunodeficiency Virus Type 1 RNA in Plasma

This Article

	Full Text
	Full Text (PDF)
	An erratum has been published
	Alert me when this article is cited
	Alert me if a correction is posted

Services

	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new issues of the journal
	Download to citation manager
	Reprints and Permissions
	Copyright Information
	Books from ASM Press
	MicrobeWorld

Citing Articles

	Citing Articles via HighWire
	Citing Articles via Google Scholar

Google Scholar

	Articles by Murphy, D. G.
	Articles by Vincelette, J.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Murphy, D. G.
	Articles by Vincelette, J.

Previous Article | Next Article

Journal of Clinical Microbiology, November 2000, p. 4034-4041, Vol. 38, No. 11
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Multicenter Comparison of Roche COBAS AMPLICOR MONITOR Version 1.5, Organon Teknika NucliSens QT with Extractor, and Bayer Quantiplex Version 3.0 for Quantification of Human Immunodeficiency Virus Type 1 RNA in Plasma

Donald G. Murphy,¹^,²^,^* Louise Côté,³ Micheline Fauvel,¹ Pierre René,⁴ and Jean Vincelette²^,⁵

Laboratoire de Santé Publique du Québec, Sainte-Anne-de-Bellevue,¹ Département de Microbiologie et Immunologie, Université de Montréal,² Centre Universitaire de Santé McGill, Hôpital Royal Victoria,⁴ and Centre Hospitalier de l'Université de Montréal, Hôpital Saint-Luc,⁵ Montréal, and Centre Hospitalier de l'Université Laval du Centre Hospitalier Universitaire de Québec, Sainte-Foy,³ Québec, Canada

Received 8 June 2000/Returned for modification 1 August 2000/Accepted 23 August 2000

The performance and characteristics of Roche COBAS AMPLICOR HIV-1 MONITOR version 1.5 (CA MONITOR 1.5) UltraSensitive (usCAMONITOR 1.5) and Standard (stCA MONITOR 1.5) procedures, OrganonTeknika NucliSens HIV-1 RNA QT with Extractor (NucliSens), andBayer Quantiplex HIV RNA version 3.0 (bDNA 3.0) were comparedin a multicenter trial. Samples used in this study included 460plasma specimens from human immunodeficiency virus (HIV) type1 (HIV-1)-infected persons, 100 plasma specimens from HIV antibody(anti-HIV)-negative persons, and culture supernatants of HIV-1subtype A to E isolates diluted in anti-HIV-negative plasma. Overall,bDNA 3.0 showed the least variation in RNA measures upon repeattesting. For the Roche assays, usCA MONITOR 1.5 displayed lessvariation in RNA measures than stCA MONITOR 1.5. NucliSens, atan input volume of 2 ml, showed the best sensitivity. Deming regressionanalysis indicated that the results of all three assays were significantlycorrelated (P < 0.0001). However, the mean difference in valuesbetween CA MONITOR 1.5 and bDNA 3.0 (0.274 log₁₀ RNA copies/ml;95% confidence interval, 0.192 to 0.356) was significantly differentfrom 0, indicating that CA MONITOR 1.5 values were regularly higherthan bDNA 3.0 values. Upon testing of 100 anti-HIV-negative plasmaspecimens, usCA MONITOR 1.5 and NucliSens displayed 100% specificity,while bDNA 3.0 showed 98% specificity. NucliSens quantified 2of 10 non-subtype B viral isolates at 1 log₁₀ lower than bothCA MONITOR 1.5 and bDNA 3.0. For NucliSens, testing of specimenswith greater than 1,000 RNA copies/ml at input volumes of 0.1,0.2, and 2.0 ml did not affect the quality of results. Additionalfactors differing between assays included specimen throughputand volume requirements, limit of detection, ease of execution,instrument work space, and costs of disposal. These characteristics,along with assay performance, should be considered when one isselecting a viral loadassay.

^* Corresponding author. Mailing address: Laboratoire de Santé Publique du Québec, 20045 Chemin Sainte-Marie, Sainte-Anne-de-Bellevue,Québec, Canada H9X 3R5. Phone: (514) 457-2070. Fax: (514) 457-6346.E-mail: dmurphy{at}lspq.org.

Journal of Clinical Microbiology, November 2000, p. 4034-4041, Vol. 38, No. 11
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

This article has been cited by other articles:

Holguin, A., Lopez, M., Molinero, M., Soriano, V. (2008). Performance of Three Commercial Viral Load Assays, Versant Human Immunodeficiency Virus Type 1 (HIV-1) RNA bDNA v3.0, Cobas AmpliPrep/Cobas TaqMan HIV-1, and NucliSens HIV-1 EasyQ v1.2, Testing HIV-1 Non-B Subtypes and Recombinant Variants. J. Clin. Microbiol. 46: 2918-2923 [Abstract] [Full Text]
Schutten, M., Peters, D., Back, N. K. T., Beld, M., Beuselinck, K., Foulongne, V., Geretti, A.-M., Pandiani, L., Tiemann, C., Niesters, H. G. M. (2007). Multicenter Evaluation of the New Abbott RealTime Assays for Quantitative Detection of Human Immunodeficiency Virus Type 1 and Hepatitis C Virus RNA. J. Clin. Microbiol. 45: 1712-1717 [Abstract] [Full Text]
McClernon, D. R., Vavro, C., St. Clair, M. (2006). Evaluation of a real-time nucleic Acid sequence-based amplification assay using molecular beacons for detection of human immunodeficiency virus type 1.. J. Clin. Microbiol. 44: 2280-2282 [Abstract] [Full Text]
Swanson, P., de Mendoza, C., Joshi, Y., Golden, A., Hodinka, R. L., Soriano, V., Devare, S. G., Hackett, J. Jr. (2005). Impact of Human Immunodeficiency Virus Type 1 (HIV-1) Genetic Diversity on Performance of Four Commercial Viral Load Assays: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT. J. Clin. Microbiol. 43: 3860-3868 [Abstract] [Full Text]
Konnick, E. Q., Williams, S. M., Ashwood, E. R., Hillyard, D. R. (2005). Evaluation of the COBAS Hepatitis C Virus (HCV) TaqMan Analyte-Specific Reagent Assay and Comparison to the COBAS Amplicor HCV Monitor V2.0 and Versant HCV bDNA 3.0 Assays. J. Clin. Microbiol. 43: 2133-2140 [Abstract] [Full Text]
Antunes, R., Figueiredo, S., Bartolo, I., Pinheiro, M., Rosado, L., Soares, I., Lourenco, H., Taveira, N. (2003). Evaluation of the Clinical Sensitivities of Three Viral Load Assays with Plasma Samples from a Pediatric Population Predominantly Infected with Human Immunodeficiency Virus Type 1 Subtype G and BG Recombinant Forms. J. Clin. Microbiol. 41: 3361-3367 [Abstract] [Full Text]
Weusten, J. J. A. M., Wouters, P. A. W. M., van Zuijlen, M. C. A., van de Wiel, P. A. (2002). Stochastic processes defining sensitivity and variability of internally calibrated quantitative NASBA-based viral load assays. Nucleic Acids Res 30: e137-e137 [Abstract] [Full Text]
Chernoff, D. N. (2002). The Significance of HIV Viral Load Assay Precision: A Review of the Package Insert Specifications of Two Commercial Kits. J Int Assoc Physicians AIDS Care (Chic Ill) 1: 134-140 [Abstract]
Trimoulet, P., Halfon, P., Pohier, E., Khiri, H., Chene, G., Fleury, H. (2002). Evaluation of the VERSANT HCV RNA 3.0 Assay for Quantification of Hepatitis C Virus RNA in Serum. J. Clin. Microbiol. 40: 2031-2036 [Abstract] [Full Text]
Weusten, J. J. A. M., Carpay, W. M., Oosterlaken, T. A. M., van Zuijlen, M. C. A., van de Wiel, P. A. (2002). Principles of quantitation of viral loads using nucleic acid sequence-based amplification in combination with homogeneous detection using molecular beacons. Nucleic Acids Res 30: e26-e26 [Abstract] [Full Text]
Kellogg, J. A., Atria, P. V., Sanders, J. C., Eyster, M. E. (2001). Intra- and Interlaboratory Variabilities of Results Obtained with the Quantiplex Human Immunodeficiency Virus Type 1 RNA bDNA Assay, Version 3.0. CVI 8: 560-563 [Abstract] [Full Text]

Antimicrob. Agents Chemother.	Clin. Microbiol. Rev.

Clin. Vaccine Immunol.	ALL ASM JOURNALS